A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein.

The lentiviral vector system based on human immunodeficiency virus type 1 (HIV-1) is used extensively in gene therapy trials of neurological and neurodegenerative diseases. Retrograde axonal transport of viral vectors offers a great advantage to the delivery of genes into neuronal cell bodies that are situated in regions distant from the injection site. Pseudotyping of HIV-1-based vectors with selective variants of rabies virus glycoprotein (RV-G) increases gene transfer via retrograde transport into the central nervous system. Because large-scale application for gene therapy trials requires high titer stocks of the vector, pseudotyping of a lentiviral vector that produces more efficient retrograde transport is needed. In the present study, we developed a novel vector system for highly efficient retrograde gene transfer by pseudotyping an HIV-1 vector with a fusion envelope glycoprotein (termed FuG-B) in which the cytoplasmic domain of RV-G was substituted by the corresponding part of vesicular stomatitis virus glycoprotein. The FuG-B pseudotype shifted the transducing property of the lentiviral vector and enhanced the retrograde transport-mediated gene transfer into different brain regions innervating the striatum with greater efficiency than that of the RV-G pseudotype in mice. In addition, injection of the FuG-B-pseudotyped vector into monkey striatum (caudate and putamen) allowed for highly efficient gene delivery into the nigrostriatal dopamine system, which is a major target for gene therapy of Parkinson's disease. Our strategy provides a powerful tool for the treatment of certain neurological and neurodegenerative diseases by promoting retrograde gene delivery via a lentiviral vector.

[1]  V. Baekelandt,et al.  Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  G. Mentis,et al.  Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins , 2006, Journal of Neuroscience Methods.

[3]  W. Staines,et al.  Efferent projections of the anterior perirhinal cortex in the rat , 1996, The Journal of comparative neurology.

[4]  Jody A. Vandergriff,et al.  Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  N. Tordo,et al.  Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer , 2009, Genetic vaccines and therapy.

[6]  N. Mazarakis,et al.  Lentiviral vectors for treating and modeling human CNS disorders , 2004, The journal of gene medicine.

[7]  R. Doolittle,et al.  Homology between the glycoproteins of vesicular stomatitis virus and rabies virus , 1982, Journal of virology.

[8]  Kazuto Kobayashi,et al.  Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein. , 2007, Human gene therapy.

[9]  L. Albritton,et al.  The Membrane-Proximal Domain of Vesicular Stomatitis Virus G Protein Functions as a Membrane Fusion Potentiator and Can Induce Hemifusion , 2002, Journal of Virology.

[10]  S. Karlsson,et al.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[12]  J. Goudreau,et al.  Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. , 2005, Brain research. Molecular brain research.

[13]  B. J. Baumgartner,et al.  Neuroprotection of Spinal Motoneurons Following Targeted Transduction with an Adenoviral Vector Carrying the Gene for Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.

[14]  A. Kingsman,et al.  Stable gene transfer to the nervous system using a non-primate lentiviral vector , 1999, Gene Therapy.

[15]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. H. Tignor,et al.  Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor , 1993, Journal of virology.

[17]  M. Schachner,et al.  The Neural Cell Adhesion Molecule Is a Receptor for Rabies Virus , 1998, Journal of Virology.

[18]  Patrick Aebischer,et al.  Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson's disease , 2006, Neurobiology of Disease.

[19]  J. Rose,et al.  Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus , 1993, Journal of virology.

[20]  Xian-Yang Zhang,et al.  LSU Digital Commons LSU Digital Commons Altering the tropism of lentiviral vectors through pseudotyping Altering the tropism of lentiviral vectors through pseudotyping , 2022 .

[21]  B. Kieffer,et al.  Low‐affinity nerve‐growth factor receptor (P75NTR) can serve as a receptor for rabies virus , 1998, The EMBO journal.

[22]  Z. Fu,et al.  Rabies virus quasispecies: implications for pathogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. K. Sapru,et al.  Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi , 2006, Experimental Neurology.

[24]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[25]  Philippe Hantraye,et al.  Applications of lentiviral vectors for biology and gene therapy of neurological disorders. , 2008, Current gene therapy.

[26]  D. Kirik,et al.  Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. , 2004, Human gene therapy.

[27]  J. Johnson,et al.  Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins , 1997, Journal of virology.

[28]  R. Vertes.  Differential projections of the infralimbic and prelimbic cortex in the rat , 2004, Synapse.

[29]  W. Cowan,et al.  A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis) , 1984, The Journal of comparative neurology.

[30]  P. Carmeliet,et al.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model , 2004, Nature.

[31]  M. Gastka,et al.  Rabies virus binding to the nicotinic acetylcholine receptor alpha subunit demonstrated by virus overlay protein binding assay. , 1996, The Journal of general virology.

[32]  Hideki Mochizuki,et al.  High-Titer Human Immunodeficiency Virus Type 1-Based Vector Systems for Gene Delivery into Nondividing Cells , 1998, Journal of Virology.

[33]  P. Cosson.  Direct interaction between the envelope and matrix proteins of HIV‐1. , 1996, The EMBO journal.

[34]  N. Mazarakis,et al.  Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. , 2005, Human gene therapy.

[35]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Compans,et al.  Assembly of Animal Viruses at Cellular Membranes , 1988 .

[37]  C. Rosenblad,et al.  Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct , 2005, Experimental Neurology.

[38]  M. Whitt,et al.  Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant , 1989, Journal of virology.

[39]  J. Mallet,et al.  1‐methyl‐4‐phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutase , 2006, Journal of neuroscience research.

[40]  C. Robison,et al.  The Membrane-Proximal Stem Region of Vesicular Stomatitis Virus G Protein Confers Efficient Virus Assembly , 2000, Journal of Virology.

[41]  A. Kingsman,et al.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. , 2001, Human molecular genetics.

[42]  Terina N. Martinez,et al.  Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  K. Keyvanfar,et al.  Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. , 2004, Blood.

[44]  E. Boritz,et al.  Requirement for a non‐specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus , 1998, The EMBO journal.

[45]  K. Simons,et al.  The budding mechanisms of enveloped animal viruses. , 1980, The Journal of general virology.

[46]  D. S. Zahm,et al.  The patterns of afferent innervation of the core and shell in the “Accumbens” part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro‐gold , 1993, The Journal of comparative neurology.

[47]  A. MacKenzie,et al.  IAP family proteins delay motoneuron cell death in vivo , 2000, The European journal of neuroscience.